Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials

被引:8
|
作者
Tsai, Tou-Yuan [1 ,2 ]
Wang, Shih-Hao [2 ,3 ,4 ]
Lee, Yi-Kung [1 ,2 ]
Su, Yung-Cheng [1 ,2 ]
机构
[1] Tzu Chi Univ, Sch Med, Hualien, Taiwan
[2] Dalin Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Emergency Dept, Chiayi, Taiwan
[3] Chang Gung Mem Hosp Chiayi, Dept Phys Med & Rehabil, Chiayi, Taiwan
[4] Natl Taiwan Sport Univ, Coll Management, Dept Recreat & Leisure Ind Management, Taoyuan, Taiwan
来源
BMJ OPEN | 2018年 / 8卷 / 08期
关键词
ginkgo biloba extract; acute mountain sickness; meta-analysis; HIGH-ALTITUDE; ACETAZOLAMIDE; PROPHYLAXIS; EGB-761; EDEMA;
D O I
10.1136/bmjopen-2018-022005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Trials of ginkgo biloba extract (GBE) for the prevention of acute mountain sickness (AMS) have been published since 1996. Because of their conflicting results, the efficacy of GBE remains unclear. We performed a systematic review and meta-analysis to assess whether GBE prevents AMS. Methods The Cochrane Library, EMBASE, Google Scholar and PubMed databases were searched for articles published up to 20 May 2017. Only randomised controlled trials were included. AMS was defined as an Environmental Symptom Questionnaire Acute Mountain Sickness-Cerebral score 0.7 or Lake Louise Score 3 with headache. The main outcome measure was the relative risk (RR) of AMS in participants receiving GBE for prophylaxis. Meta-analyses were conducted using random-effects models. Sensitivity analyses, subgroup analyses and tests for publication bias were conducted. Results Seven study groups in six published articles met all eligibility criteria, including the article published by Leadbetter et al, where two randomised controlled trials were conducted. Overall, 451 participants were enrolled. In the primary meta-analysis of all seven study groups, GBE showed trend of AMS prophylaxis, but it is not statistically significant (RR=0.68; 95%CI 0.45 to 1.04; p=0.08). The I-2 statistic was 58.7% (p=0.02), indicating substantial heterogeneity. The pooled risk difference (RD) revealed a significant risk reduction in participants who use GBE (RD=-25%; 95%CI, from a reduction of 45% to 6%; p=0.011) The results of subgroup analyses of studies with low risk of bias, low starting altitude (<2500m), number of treatment days before ascending and dosage of GBE are not statistically significant. Conclusion The currently available data suggest that although GBE may tend towards AMS prophylaxis, there are not enough data to show the statistically significant effect of GBE on preventing AMS. Further large randomised controlled studies are warranted.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Traditional Chinese medicine for acute mountain sickness prevention:A systematic review and meta-analysis of randomized controlled trials
    Hui Luo
    Xing Liao
    Qiaoling Tang
    Qian Wang
    [J]. Journal of Traditional Chinese Medical Sciences, 2023, 10 (01) : 73 - 82
  • [2] Dexamethasone for the prevention of acute mountain sickness: Systematic review and meta-analysis
    Tang, Enjie
    Chen, Yu
    Luo, Yongjun
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 173 (02) : 133 - 138
  • [3] Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials
    Zheng, W.
    Xiang, Y. -Q.
    Ng, C. H.
    Ungvari, G. S.
    Chiu, H. F. K.
    Xiang, Y. -T.
    [J]. PHARMACOPSYCHIATRY, 2016, 49 (03) : 107 - 111
  • [4] Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis
    Pandit, Anil
    Karmacharya, Paras
    Pathak, Ranjan
    Giri, Smith
    Aryal, Madan R.
    [J]. JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2014, 4 (04):
  • [5] Reappraisal of Acetazolamide for the Prevention of Acute Mountain Sickness: A Systematic Review and Meta-Analysis
    Kayser, Bengt
    Dumont, Lionel
    Lysakowski, Christopher
    Combescure, Christophe
    Haller, Guy
    Tramer, Martin R.
    [J]. HIGH ALTITUDE MEDICINE & BIOLOGY, 2012, 13 (02) : 82 - 92
  • [6] Inhaled budesonide for the prevention of acute mountain sickness: A meta-analysis of randomized controlled trials
    Zhu, Xiong
    Liu, Yunrui
    Li, Na
    He, Qing
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2020, 38 (08): : 1627 - 1634
  • [7] Ginkgo biloba for Prevention of Acute Mountain Sickness: Does It Work?
    van Patot, Martha C. Tissot
    Keyes, Linda E.
    Leadbetter, Guy, III
    Hackett, Peter H.
    [J]. HIGH ALTITUDE MEDICINE & BIOLOGY, 2009, 10 (01) : 33 - 43
  • [8] Randomised, controlled trial of ginkgo biloba and acetazolamide for prevention of acute mountain sickness: the prevention of high altitude illness trial (PHAIT)
    Gertsch, JH
    Basnyat, B
    Johnson, EW
    Onopa, J
    Holck, PS
    [J]. BRITISH MEDICAL JOURNAL, 2004, 328 (7443): : 797 - 799
  • [9] Beneficial effects of Ginkgo biloba leaf extract on inflammatory markers: A systematic review and meta-analysis of the clinical trials
    Mousavi, Seyedeh Neda
    Hosseinikia, Mahboobe
    Rad, Esmaeil Yousefi
    Saboori, Somayeh
    [J]. PHYTOTHERAPY RESEARCH, 2022, 36 (09) : 3459 - 3469
  • [10] Efficacy and tolerability of Ginkgo biloba extract EGb 761®in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials
    Gauthier, Serge
    Schlaefke, Sandra
    [J]. CLINICAL INTERVENTIONS IN AGING, 2014, 9 : 2065 - 2077